Cardiospirina 81 mg Tabletas Con Cubierta Enterica

Description

Cardiospirina is presented in the form of tablets, each containing a strength of 81 mg. The formulation is designed for oral administration, providing a precise dosage for therapeutic use.

Uses and Indications

Cardioaspirina 81 mg is indicated for the prevention of cardiovascular events in patients at high risk for such events.

Limitations of Use: There are no specific teratogenic or nonteratogenic effects associated with Cardioaspirina 81 mg as per the available data.

Dosage and Administration

The medication is administered orally at a dosage of 81 mg. Healthcare professionals should ensure that the patient takes the medication as directed, adhering to the prescribed dosage. It is important to monitor the patient for any potential side effects and to provide guidance on the timing of doses to maintain consistent therapeutic levels.

Contraindications

There are no specified contraindications for the use of this product. Healthcare professionals should assess individual patient circumstances and consider any potential risks associated with the use of the product in specific populations or conditions.

Warnings and Precautions

Healthcare professionals should be aware of the following critical considerations regarding the safe use of this medication.

Warnings While specific warnings are not detailed, it is imperative that healthcare providers remain vigilant for any adverse reactions or contraindications associated with the medication. Continuous assessment of the patient's overall health status is essential to mitigate potential risks.

General Precautions Although general precautions are not explicitly outlined, practitioners should exercise caution when prescribing this medication, particularly in populations with comorbid conditions or those taking concomitant therapies. A thorough patient history and assessment of potential drug interactions are recommended to ensure safe administration.

Laboratory Tests Regular monitoring through appropriate laboratory tests is advised to evaluate the patient's response to treatment and to detect any emerging side effects. Specific tests should be determined based on the individual patient's health status and the medication's pharmacological profile.

Emergency Medical Help In the event of severe adverse reactions or anaphylactic symptoms, immediate medical intervention is crucial. Healthcare providers should instruct patients to seek emergency medical assistance if they experience any alarming symptoms.

Discontinuation of Therapy Patients should be advised to discontinue the medication and contact their healthcare provider if they experience any concerning side effects or if their condition worsens. Prompt communication can facilitate timely management of any complications that may arise.

Healthcare professionals are encouraged to remain informed about the latest guidelines and recommendations to ensure optimal patient care while using this medication.

Side Effects

Aspirin use in children and teenagers with viral infections has been associated with Reye's syndrome, a rare but serious illness that can cause liver and brain damage. This boxed warning highlights the critical risk associated with aspirin administration in this population.

Common adverse reactions observed in clinical trials and postmarketing experiences include gastrointestinal bleeding, dyspepsia, nausea, and vomiting. These reactions are frequently reported among patients and may require monitoring and management.

Less common adverse reactions include allergic reactions such as rash, urticaria, and angioedema, as well as tinnitus and hearing loss. While these events are not as prevalent, they should be considered when evaluating patient responses to treatment.

Rare adverse reactions have also been documented, including severe allergic reactions like anaphylaxis, hemolytic anemia, thrombocytopenic purpura, and gastrointestinal ulceration and perforation. These serious events necessitate immediate medical attention and intervention.

Additional adverse reactions of note include prolonged bleeding time, which may impact surgical or invasive procedures, and asthma exacerbation in aspirin-sensitive patients. Liver function abnormalities and renal impairment have also been reported, indicating the need for careful monitoring of patients with pre-existing conditions. Skin reactions, including Stevens-Johnson syndrome, have been observed and warrant consideration in the context of patient safety.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Cardiospirina 81 mg Tabletas Con Cubierta Enterica (cardioaspirin 81 mg enteric coated tablet). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use of Cardiospirina 81 mg has not been established. The safety and efficacy of this medication in pediatric patients remain undetermined. Therefore, caution is advised when considering its use in children, infants, and adolescents.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Cardiospirina 81 mg is contraindicated in pregnancy due to the associated risks to the fetus. The use of this medication during pregnancy may lead to adverse fetal outcomes. Healthcare professionals should advise pregnant patients to avoid the use of Cardiospirina 81 mg and consider alternative treatment options that are safer for use during pregnancy. Women of childbearing potential should be informed of these risks and the importance of discussing any medications with their healthcare provider prior to conception or during pregnancy.

Lactation

There are no specific statements regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, there are no known data on excretion in breast milk or effects on breastfed infants. Healthcare professionals should consider the absence of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to Cardiospirina 81 mg. The prescribing information does not provide any recommendations regarding dosage adjustments, special monitoring, or precautions for individuals with compromised liver function. Therefore, healthcare professionals should exercise caution and consider the overall clinical context when prescribing this medication to patients with hepatic impairment.

Overdosage

Overdosage of aspirin can lead to significant adverse effects that necessitate prompt medical intervention. The potential complications associated with aspirin overdosage include gastrointestinal bleeding, metabolic acidosis, and respiratory alkalosis.

Healthcare professionals should be vigilant for symptoms indicative of an overdose, which may manifest as tinnitus, headache, dizziness, confusion, and hyperventilation. The presence of these symptoms should raise suspicion for aspirin overdosage and warrant immediate medical attention.

In managing a suspected overdose, it is crucial to initiate supportive care and symptomatic treatment tailored to the patient's clinical presentation. If the overdose has occurred recently and the patient is alert, the administration of activated charcoal may be considered to mitigate absorption of the drug.

Overall, timely recognition and appropriate management of aspirin overdosage are essential to minimize the risk of serious complications and ensure patient safety.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Patients should be advised to take Cardiospirina 81 mg Tablets with a full glass of water to ensure proper swallowing and absorption. It is important for patients to understand that the tablets are enteric-coated, which is designed to help prevent stomach irritation. Healthcare providers should instruct patients not to crush or chew the tablets, as this may compromise the enteric coating and lead to gastrointestinal discomfort.

Patients should be informed of the importance of communicating with their healthcare provider if they are pregnant, plan to become pregnant, or are breastfeeding, as this may affect their treatment plan. Additionally, patients should be cautioned about the risk of bleeding associated with Cardiospirina, particularly if they are taking other medications that may increase the risk of bleeding.

Healthcare providers should emphasize the necessity of keeping this medication out of the reach of children and advise patients to seek medical attention immediately if an overdose is suspected. This information is crucial for ensuring patient safety and effective use of the medication.

Storage and Handling

The product is supplied in packaging that ensures its integrity and stability. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to maintain its efficacy. Additionally, the container must be kept tightly closed to prevent contamination and preserve the quality of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Cardiospirina 81 mg Tabletas Con Cubierta Enterica, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)